T 0283/11 (MVA-BN/Bavarian Nordic A/S) of 05.11.2014

European Case Law Identifier: ECLI:EP:BA:2014:T028311.20141105
Date of decision: 5 November 2014
Case number: T 0283/11
Petition for review of: -
Application number: 01991753.3
IPC class: A61K 39/285 C12N 15/39 C12N 15/863 A61K 48/00 C12N 7/04
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: MODIFIED VACCINIA ANKARA VIRUS VARIANT
Applicant name: Bavarian Nordic A/S
Opponent name: Baxter Aktiengesellschaft
Acambis, Plc.
Acambis, Inc.
Innogenetics N.V.
Oxford Biomedica (UK) Limited
Sanofi Pasteur, Inc.
Emergent Product Development Germany GmbH
VIRBAC S.A.
Board: 3.3.08
Headnote: -
Relevant legal provisions: European Patent Convention Art 108 European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 53(c)European Patent Convention Art 54 European Patent Convention Art 56 European Patent Convention Art 83 European Patent Convention Art 84 European Patent Convention R 99Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)
Keywords: Main request - requirements of the EPC met (yes)
Catchword: -
Cited cases: T 0156/84 T 1002/92 T 0464/94 T 1485/08 T 0593/09 T 0544/12
Citing cases: T 0222/11

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to maintain the patent as amended in the following version:

Description: Pages 2, 2a, and 3 to 18, received during the oral proceedings before the Board on 5 November 2014.

Claims: Nos. 1-32 of the Main Request received during the oral proceedings before the Board on 5 November 2014.

Drawings: Figures 1-11 of the patent specification as granted.